Bristol Myers Squibb (BMY) News Today

Bristol Myers Squibb (NYSE: BMY) is trading higher today after mixed news: promising clinical data and AI research partnerships are supporting upside, while near-term analyst cuts and multiple “hold” ratings are capping gains. Key items investors are watching are first‑in‑human Phase I data for Iza‑bren (EGFR x HER3 ADC) from a SystImmune collaboration, BMY’s expanded AI work in neuroscience, and recent analyst estimate revisions from Leerink/others. Below are the headlines that likely moved the stock.

• Positive Sentiment: Early clinical readout — SystImmune and Bristol Myers Squibb presented first global Phase I results for Iza‑bren (EGFR x HER3 ADC) at ESMO; the data includes activity in advanced solid tumors (including lung cancer), which supports BMY’s oncology pipeline expansion. SystImmune, Inc. and Bristol Myers Squibb Announce First Global Phase I Results of Iza-bren
• Positive Sentiment: Coverage and press release — Multiple outlets (PR Newswire / MSN) reported the Iza‑bren results, increasing visibility and investor interest in BMY’s collaboration pipeline. PR Newswire: Iza-bren Phase I Results
• Positive Sentiment: AI partnership progress — BMY’s collaboration with insitro advanced into ALS/neuroscience work, highlighting a non‑oncology growth avenue that could extend longer‑term R&D potential. Does BMY's AI Collaboration With insitro Signal a New Growth Path
• Neutral Sentiment: Brokerage stance — Wells Fargo and Weiss Ratings reaffirmed Hold ratings on BMY, keeping near‑term investor sentiment muted despite pipeline news. Wells Fargo Keeps Their Hold Rating on Bristol‑Myers Squibb
• Negative Sentiment: Analyst cuts and near‑term outlook — Leerink issued a negative outlook for BMY’s Q3 and lowered its FY2025 EPS forecast, which raises concerns about near‑term earnings momentum and likely pressured sentiment. Leerink Partnrs Has Negative Outlook for BMY Q3 Earnings
• Neutral Sentiment: Mixed analyst notes — Other research outlets (TipRanks / MarketBeat) reflect a neutral/hold consensus with some longer‑term EPS tweaks from Leerink (modest raises for FY2026‑FY2029), leaving the stock’s trajectory dependent on upcoming quarterly results and further clinical readouts. FY2025 Earnings Forecast for BMY Issued By Leerink Partnrs